<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02254317</url>
  </required_header>
  <id_info>
    <org_study_id>2014-074</org_study_id>
    <nct_id>NCT02254317</nct_id>
  </id_info>
  <brief_title>Dose-dependent Effect of Grape Seed Extract on Glucose Control in People With Impaired Glucose Tolerance</brief_title>
  <acronym>GSE3</acronym>
  <official_title>Dose-dependent Effect of Grape Seed Extract (GSE) on Glucose Control in People With Impaired Glucose Tolerance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinical Nutrition Research Center, Illinois Institute of Technology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinical Nutrition Research Center, Illinois Institute of Technology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to identify the lowest effective dose of Grape Seed Extract (GSE) on glucose&#xD;
      control in people with impaired glucose tolerance (IGT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study is a single-center, placebo-controlled, randomized, 4-arm, crossover study&#xD;
      that identify the lowest effective dose of GSE on glucose control in people with impaired&#xD;
      glucose tolerance.&#xD;
&#xD;
      A planned sample size of 20 will be recruited into the study. This study will require one&#xD;
      initial screening visit, pre-study visit, and 4 Oral Glucose Tolerance Test Days (OGTT) Days.&#xD;
      This study will take 4-6weeks per subject to complete.&#xD;
&#xD;
      The trial will initiate with one screening visit, which will last for about 3-4 hours where&#xD;
      the subjects' height, weight, BMI, waist circumference, fasting blood glucose, blood pressure&#xD;
      and heart rate will be measured and a survey related to general eating, health and exercise&#xD;
      habits will be completed. OGTT procedure will be performed to confirm IGT.&#xD;
&#xD;
      If willing and eligible to participate, a 3-day food record (2 weekdays and 1 weekend) will&#xD;
      be given at the screening visit and collected on the following pre-study Visit to assess&#xD;
      subject's baseline dietary intake and pattern. Also, subjects will be instructed to follow a&#xD;
      relatively low polyphenolic-diet at least 7 days prior to the first OGTT Day and for the&#xD;
      duration of the study. A dinner meal will be provided the day before the OGTT Day to control&#xD;
      the second meal effect from food and beverage intake of the night before the OGTT Day.&#xD;
&#xD;
      Subjects will arrive at the center in a fasting state for at least 10 hours, well hydrated&#xD;
      and rested. Each OGTT Day will require blood draws throughout the visit. After evaluation of&#xD;
      subject's health status (via anthropometric, vital sign and blood glucose measurements and&#xD;
      in-person interview), a registered nurse will place a catheter in subject's arm for the&#xD;
      purpose of multiple blood sample collections and take the initial blood draw (baseline: -1h)&#xD;
      in the fasting state. 3 test capsules with 0 mg GSE, 300 mg GSE, 600 mg GSE or 900 mg GSE (in&#xD;
      forms of: 3 placebo, 2 placebo &amp; 1 GSE, 1 placebo &amp; 2 GSE or 3 GSE. Each GSE capsule&#xD;
      containing 300 mg GSE) will be served. Thereafter, timers will be started and a glucose test&#xD;
      drink (75g glucose mixed with 250ml water) will be given right after the 0h blood sampling (1&#xD;
      h after the consumption of capsules). Subject will be instructed to finish the drink in 5&#xD;
      minutes (min). From this point forward, blood sample will be collected at 30 min, 1h, 2hand&#xD;
      3h for assessment of changes in metabolic markers. The sequence of receiving the capsules&#xD;
      treatment at each visit will be randomly assigned based on computer generated sequences.&#xD;
&#xD;
      OGTT Day visits will be placed at least 3 days apart as well.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 15, 2014</start_date>
  <completion_date type="Actual">July 1, 2015</completion_date>
  <primary_completion_date type="Actual">June 27, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in plasma metabolic markers over 4 hour Oral Glucose Tolerance Test (OGTT) after administration of GSE capsules (containing 300mg, 600mg or 900mg Grape seed extract) compared to 0 mg placebo.</measure>
    <time_frame>4 hr</time_frame>
    <description>plasma metabolic markers over 4 hour Oral Glucose Tolerance Test (OGTT)</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Impaired Glucose Tolerance</condition>
  <arm_group>
    <arm_group_label>0 mg placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Not containing GSE (Placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>300 mg GSE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Containing 300 mg of GSE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>600 mg GSE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Containing 600 mg of GSE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>900 mg GSE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Containing 900 mg of GSE</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>0 mg placebo</intervention_name>
    <description>Not containing GSE (Placebo)</description>
    <arm_group_label>0 mg placebo</arm_group_label>
    <other_name>Placebo Comparator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>300 mg GSE</intervention_name>
    <description>300 mg GSE</description>
    <arm_group_label>300 mg GSE</arm_group_label>
    <other_name>Active Comparator1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>600 mg GSE</intervention_name>
    <description>Containing 600 mg of GSE</description>
    <arm_group_label>600 mg GSE</arm_group_label>
    <other_name>Active Comparator2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>900 mg GSE</intervention_name>
    <description>Containing 900 mg of GSE</description>
    <arm_group_label>900 mg GSE</arm_group_label>
    <other_name>Active Comparator3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged between 40 to 65 years old male/female&#xD;
&#xD;
          -  Body Mass Index (BMI) less than 35kg/m2&#xD;
&#xD;
          -  Fasting blood sugar between 100-125 mg/dL&#xD;
&#xD;
          -  Confirmed impaired glucose tolerance (IGT) upon 2 hr OGTT screening test (≥ 140 mg/dL&#xD;
             &lt; 200mg/dL)&#xD;
&#xD;
          -  Non-smoker&#xD;
&#xD;
          -  No clinical evidence of cardiovascular, metabolic, respiratory, renal,&#xD;
             gastrointestinal or hepatic disease&#xD;
&#xD;
          -  Not taking any medications or dietary supplements that would interfere with outcomes&#xD;
             of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Past smokers: abstinence for less than 2 years&#xD;
&#xD;
          -  Men and women who smoke&#xD;
&#xD;
          -  Men and women with known or suspected food intolerance, allergies or hypersensitivity&#xD;
             to the study materials or closely related compound or any their stated ingredients.&#xD;
&#xD;
          -  Men and women known to have/diagnosed with diabetes mellitus&#xD;
&#xD;
          -  Men and women who have fasting blood glucose concentrations ≥126 mg/dL&#xD;
&#xD;
          -  Men and women with documented vascular disease, e.g., heart failure, myocardial&#xD;
             infarction, stroke, angina, related surgeries.&#xD;
&#xD;
          -  Men and women with cancer other than non-melanoma skin cancer in previous 5 years.&#xD;
&#xD;
          -  Men and women who are taking medication or dietary supplements that may interfere with&#xD;
             the outcomes of the study; e.g., antioxidant supplements, anti-inflammation, lipid&#xD;
             lowering medication. Subjects may choose to go off dietary supplements (requires 30&#xD;
             days washout).&#xD;
&#xD;
          -  Men and women who have donated blood within 3 months of the screening visit and blood&#xD;
             donors/participants for whom participation in this study will result in having donated&#xD;
             more than 1500 milliliters of blood in the previous 12 months.&#xD;
&#xD;
          -  Substance (alcohol or drug) abuse within the last 2 years.&#xD;
&#xD;
          -  Excessive coffee and tea consumers (&gt; 4 cups/day)&#xD;
&#xD;
          -  Unstable weight: gained or lost weight +/- 5 lbs in previous 3 months&#xD;
&#xD;
          -  Women who are known to be pregnant or who are intending to become pregnant over the&#xD;
             course of the study and women who are lactating.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Britt Burton-Freeman, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Illinois Institute of Technology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eunyoung Park</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 29, 2014</study_first_submitted>
  <study_first_submitted_qc>September 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2014</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Impaired Glucose Tolerance</keyword>
  <keyword>Oral Glucose Tolerance Test</keyword>
  <keyword>Grape Seed Extract</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

